Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

Breast Cancer Clinical Trial

— LAPADO  

Official title:

Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01172223
• Other study ID #: LAPADO-Study
• Secondary ID: 2007-000924-42
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: July 28, 2010
• Last updated: November 1, 2016
• Start date: September 2007
• Est. completion date: December 2013

Study information

• Verified date: October 2016
• Source: Sana-Klinikum Lichtenberg
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Open-label, multicenter phase I/II trial. Patients with HER2-positive (overexpressing or amplified), invasive breast cancer with T1c N1-2 or T2 N0-2 disease will be treated with

• Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m^2 i.v. day 1 q3 weeks),

• Paclitaxel (175 mg/m^2 i.v. day 1 q3 weeks), and

• Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery) Treatment is planned for 6 cycles unless there is evidence of unacceptable toxicity, disease progression or inadequate efficacy (defined as a decrease in tumor size <25% after 4 courses measured by ultrasound or MR-mammography), or if the patient requested to be released.

Description:

Breast cancer is the most common malignancy affecting females in northern Europe and North America, corresponding to an age-corrected annual incidence of 100 to 120 per 100000 females. Approximately 30-40% of all patients treated with curative intent will develop metastatic disease. Perioperative systemic treatment has made a major impact on relapse-free and overall survival of women with early-stage breast cancer [ , ] with therapeutic strategies being based on the endocrine responsiveness and the estimated risk of relapse defined by tumor size, axillary lymph node involvement, histologic and nuclear grade, lymphatic and/or vascular invasion, HER2/neu-overexpression and age [ ]. Perioperative therapy has traditionally been administered postoperatively, but chemotherapy is increasingly utilized in the preoperative setting as it can significantly improve the rate of breast conserving surgery, and new regimens can be evaluated rapidly and more precisely.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: December 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed breast cancer

• T1c N1-2 or T2 N0-2 disease

• HER2-positive tumours with 3+ intensity on immunohistochemical staining for HER2 or amplification of the HER2 gene on fluorescence in situ hybridization (FISH)

• No prior systemic treatment regimens for breast cancer

• Adequate hematologic function (ANC 1500 cells/µl, platelet count 100000/µl, and hemoglobin 8g/dl).

• Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or creatinine clearance >60 ml/min

• Bilirubin level < 1.5 X ULN

• Normal cardiac function with a left ventricular ejection fraction of at least 50% (as assessed by quantitative echocardiogram or MUGA scan)

• Karnofsky performance status 80%

• Age 18 years

• If the patient is of childbearing potential, she agrees to: comply with effective contraceptive measures, has been using adequate contraception since the last menses, will use adequate contraception during the study, and has a negative pregnancy test within one week of study entry

• Written informed consent prior to admission to this study

Exclusion Criteria:

• Male patients

• Inflammatory or bilateral breast cancer

• Evidence of distant metastases

• Previous systemic or local treatment for breast cancer (including surgery, radiotherapy, cytotoxic and endocrine treatments)

• Past or current history of other neoplasms, except for

• Curatively treated non-melanoma skin cancer

• Adequately treated in situ carcinoma of the cervix

• Other cancer curatively treated and with no evidence of disease for at least 5 years

• Significant cardiac disease, including angina pectoris, severe cardiac arrhythmia requiring medication, severe conduction abnormalities, clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, poorly uncontrolled hypertension (resting diastolic blood pressure >115 mmHg), prior myocardial infarction, CHF, or other cardiomyopathy

• Preexisting sensoric or motor polyneuropathy Grade 2 according to NCI CTC

• Serious intercurrent medical or psychiatric illness, including serious active infection

• Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry.

• Detained persons or prisoners

• Pregnant or nursing women

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Myocet (Non-pegylated liposomal doxorubicin (NPLD))
60 mg/m^2 i.v. day 1 q3 weeks
• Paclitaxel
175 mg/m^2 i.v. day 1 q3 weeks
• Lapatinib (GW572016, Tykerb)
750-1500 mg/d orally daily until the day of the definitive surgery

Locations

Country	Name	City	State
Germany	Sana Klinikum Lichtenberg	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
Prof Dirk Elling

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the optimal doses for NPLD, paclitaxel and lapatinib (phase I)		every 3 weeks	Yes
Primary	Evaluate the pathological response to NPLD, paclitaxel and lapatinib (phase II)		every 6 weeks	Yes